Duloxetine: A dual reuptake inhibitor

Annals of Pharmacotherapy

Volumn 38, Issue 12, 2004, Pages 2078-2085

  Dugan, Sara E ^b,c   Fuller, Matthew A ^a,b,d,e,f  

^a ELI LILLY AND COMPANY   (United States)

^b Pharmacy 119B   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d Louis Stokes Cleveland Dept Vet A   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TOLEDO   (United States)

Author keywords

Duloxetine; Major depressive disorder; Serotonin norepinephrine reuptake inhibitor

Indexed keywords

DULOXETINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TYRAMINE; VENLAFAXINE;

ANOREXIA; ANXIETY DISORDER; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RHINITIS; SEXUAL DYSFUNCTION; SOMNOLENCE; STRESS INCONTINENCE; TREMOR; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 12844267437     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E084     Document Type: Review

References (20)

1. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3-21.
2. Davidson JRT, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999;60(suppl 7):4-9.
3. Frank E, Judge R. Treatment recommendations versus treatment realities: recognizing the rift and understanding the consequences. J Clin Psychiatry 2001;62(suppl 22):10-5.
4. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-80.
5. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2000;24:511-21.
6. Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology 2003;28:1685-93.
7. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000;40:161-7.
8. Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan H-Y, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003;31:1142-50.
9. Skinner MH, Kuan H-Y, Pan A, Sathirakul K, Knadler MP, Gonzales CR, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-7.
10. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90.
11. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15.
12. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-31.
13. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-32.
14. Detke M, Gilaberte I, Perahia DG, Wang F, Lee TC, Tran P, et al. Duloxetine vs. placebo in the prevention of relapse of major depressive disorder. Presented at: European College of Neuropsychopharmacology, Prague, September 20-24, 2003.
15. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237-44.
16. Wohlreich MM, Kennedy JS, Mallinckrodt CH, Raskin J, Watkin J, Tran PV. Open label duloxetine treatment of major depression in patients age ≥65. Presented at: 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17-22, 2003.
17. Diagnostic and statistical manual. Washington, DC: American Psychiatric Association, 4th ed. 2000.
18. Package insert. Effexor (venlafaxine). Philadelphia: Wyeth Pharmaceuticals, May 2004.
19. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8.
20. Brannan SK, Detke MJ, Wang F, Mallinckrodt CH, Watkin JG, Tran PV, et al. Comparison of sexual functioning in patients receiving duloxetine or paroxetine: acute- and long-term data. Presented at: 156th Annual Meeting of the American Psychiatric Association, San Francisco, May 17-22, 2003.